The global amyotrophic lateral sclerosis treatment market size reached US$ 754.4 Million in 2023. Looking forward, the market is projected to reach US$ 1,112.5 Million by 2032, exhibiting a growth rate (CAGR) of 4.41% during 2023-2032.
Amyotrophic Lateral Sclerosis (ALS) Treatment refers to a degenerative disease that affects the nerve cells in the spinal cord and brain, resulting in loss of muscle control. It primarily occurs due to gene mutation, disorganized immune response, chemical imbalance, etc. Some of the common symptoms of ALS include muscle stiffness, twitching of the muscles, weakness in the legs or arms, cognitive and behavioral changes, trouble in swallowing, slurred speech, etc. The diagnosis of ALS relies on medical history, physical examination, electrodiagnostic testing, and neuroimaging.
Furthermore, several NGOs and private organizations are undertaking numerous initiatives to increase awareness regarding the diagnosis and treatment of ALS among the masses. This, in turn, is creating a positive outlook for the market. Additionally, the growing penetration of targeted and symptomatic treatment options for ALS is acting as a significant growth-inducing factor.
Moreover, the elevating focus on clinical trials and faster approval of oral drugs for ALS treatment is also bolstering the market growth. Moreover, the increasing strategic collaborations among various research institutes to develop innovative treatment procedures that aim at enhancing muscle function, immune modulation, and neuroprotection are further catalyzing the global market. In the coming years, the continuous upgradation of healthcare infrastructures along with elevating penetration of refurbishment policies will continue to drive the global amyotrophic lateral sclerosis (ALS) treatment market.
2. What is the expected growth rate of the global amyotrophic lateral sclerosis treatment market during 2024-2032?
3. What are the key factors driving the global amyotrophic lateral sclerosis treatment market?
4. What has been the impact of COVID-19 on the global amyotrophic lateral sclerosis treatment market?
5. What is the breakup of the global amyotrophic lateral sclerosis treatment market based on the treatment?
6. What is the breakup of the global amyotrophic lateral sclerosis treatment market based on the distribution channel?
7. What are the key regions in the global amyotrophic lateral sclerosis treatment market?
8. Who are the key players/companies in the global amyotrophic lateral sclerosis treatment market?
Amyotrophic Lateral Sclerosis (ALS) Treatment refers to a degenerative disease that affects the nerve cells in the spinal cord and brain, resulting in loss of muscle control. It primarily occurs due to gene mutation, disorganized immune response, chemical imbalance, etc. Some of the common symptoms of ALS include muscle stiffness, twitching of the muscles, weakness in the legs or arms, cognitive and behavioral changes, trouble in swallowing, slurred speech, etc. The diagnosis of ALS relies on medical history, physical examination, electrodiagnostic testing, and neuroimaging.
Amyotrophic Lateral Sclerosis Treatment Market Trends
The rising incidences of neurodegenerative disorders due to changing lifestyle patterns and hectic schedules of the individuals are primarily driving the Amyotrophic Lateral Sclerosis Treatment treatment market. Besides this, the expanding geriatric population, who are more susceptible to such neurological ailments, is also augmenting the market growth.Furthermore, several NGOs and private organizations are undertaking numerous initiatives to increase awareness regarding the diagnosis and treatment of ALS among the masses. This, in turn, is creating a positive outlook for the market. Additionally, the growing penetration of targeted and symptomatic treatment options for ALS is acting as a significant growth-inducing factor.
Moreover, the elevating focus on clinical trials and faster approval of oral drugs for ALS treatment is also bolstering the market growth. Moreover, the increasing strategic collaborations among various research institutes to develop innovative treatment procedures that aim at enhancing muscle function, immune modulation, and neuroprotection are further catalyzing the global market. In the coming years, the continuous upgradation of healthcare infrastructures along with elevating penetration of refurbishment policies will continue to drive the global amyotrophic lateral sclerosis (ALS) treatment market.
Key Market Segmentation
This report provides an analysis of the key trends in each sub-segment of the global amyotrophic lateral sclerosis treatment market report, along with forecasts at the global, regional and country level from 2024-2032. The report has categorized the market based on ALS type, drug type, diagnosis type, treatment and distribution channel.Breakup by ALS Type:
- Sporadic ALS
- Familial ALS
Breakup by Drug Type:
- Marketed Drugs
- Emerging Drugs
Breakup by Diagnosis Type:
- Electromyogram
- MRI
- Blood and Urine Tests
- Spinal Tap
- Muscle Biopsy
Breakup by Treatment:
- Medication
- Stem Cell Therapy
- Others
Breakup by Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape
The competitive landscape of the industry has also been examined along with the profiles of the key players being AB Science, Ascend Pharmaceuticals LLC, BrainStorm Cell Therapeutics Inc., Corestem Inc., Cytokinetics Inc., Eledon Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., ITF Pharma (Italfarmaco S.p.A), Mitsubishi Chemical Group Corpotion, Revalesio Corporation and Treeway B.V.Key Questions Answered in This Report
1. What was the size of the global amyotrophic lateral sclerosis treatment market in 2023?2. What is the expected growth rate of the global amyotrophic lateral sclerosis treatment market during 2024-2032?
3. What are the key factors driving the global amyotrophic lateral sclerosis treatment market?
4. What has been the impact of COVID-19 on the global amyotrophic lateral sclerosis treatment market?
5. What is the breakup of the global amyotrophic lateral sclerosis treatment market based on the treatment?
6. What is the breakup of the global amyotrophic lateral sclerosis treatment market based on the distribution channel?
7. What are the key regions in the global amyotrophic lateral sclerosis treatment market?
8. Who are the key players/companies in the global amyotrophic lateral sclerosis treatment market?
Table of Contents
1 Preface3 Executive Summary13 Value Chain Analysis15 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Amyotrophic Lateral Sclerosis Treatment Market
6 Market Breakup by ALS Type
7 Market Breakup by Drug Type
8 Market Breakup by Diagnosis Type
9 Market Breakup by Treatment
10 Market Breakup by Distribution Channel
11 Market Breakup by Region
12 SWOT Analysis
14 Porters Five Forces Analysis
16 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- AB Science
- Ascend Pharmaceuticals LLC
- BrainStorm Cell Therapeutics Inc.
- Corestem Inc.
- Cytokinetics Inc.
- Eledon Pharmaceuticals Inc.
- Ionis Pharmaceuticals Inc.
- ITF Pharma (Italfarmaco S.p.A)
- Mitsubishi Chemical Group Corpotion
- Revalesio Corporation
- Treeway B.V.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 137 |
| Published | April 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 754.4 Million |
| Forecasted Market Value ( USD | $ 1110 Million |
| Compound Annual Growth Rate | 4.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 11 |
